نتایج جستجو برای: mtx

تعداد نتایج: 3366  

Journal: :Arthritis and rheumatism 2005
Hiroyuki Nakaya Tominaga Shimizu Ken-ichi Isobe Keiji Tensho Takahiro Okabe Yukio Nakamura Masashi Nawata Hideki Yoshikawa Kunio Takaoka Shigeyuki Wakitani

OBJECTIVE To evaluate whether microbubble-enhanced ultrasound (US) treatment promotes the delivery of methotrexate (MTX) into synovial cells and the enhanced antiinflammatory effects of intraarticular MTX therapy in a rabbit arthritis model. METHODS Arthritis was induced in both knees of 53 rabbits by immunization with ovalbumin. MTX including a microbubble agent was then injected into the le...

آذرمی, یداالله, خاکی, آرش, خاکی, امیر افشین, روشنگر, لیلا, صراطی نوری, حامد, نوری, محمد,

Introduction & Objectives: Methotrexate (MTX) is a chemotherapeutic agent that used for the treatment of a variety of tumors and inflammatory diseases. The aim of this study was planed to see the role of human growth hormone (hGH) on testis recovery after treatment with MTX in rat. Materials & Methods: In this experimental study the fifty male wistar rat were selected and randomly divided ...

2014
Jeroen P Jansen Felicity Buckley Fred Dejonckheere Sarika Ogale

OBJECTIVE To compare biologics as monotherapy or in combination with methotrexate (MTX) in terms of patient reported outcomes (PROs) in RA patients with an inadequate response to conventional DMARDs (DMARD-IR). METHODS With a systematic literature review 17 RCTs were identified that evaluated adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, abatacept, anakinra or tocilizumab...

2014
Janet E Pope Boulos Haraoui J Carter Thorne Andrew Vieira Melanie Poulin-Costello Edward C Keystone

OBJECTIVE To determine if withdrawing methotrexate (MTX) after 6 months of combination etanercept (ETN)+MTX, in MTX-inadequate responders with active rheumatoid arthritis (RA), is non-inferior to continuing ETN+MTX. METHODS Tumour necrosis factor-inhibitor naïve RA patients with disease activity score 28 (DAS28)≥3.2, swollen joint count≥3, despite stable MTX, were treated with ETN+MTX for 6 m...

2016
Tatsuya Atsumi Kazuhiko Yamamoto Tsutomu Takeuchi Hisashi Yamanaka Naoki Ishiguro Yoshiya Tanaka Katsumi Eguchi Akira Watanabe Hideki Origasa Shinsuke Yasuda Yuji Yamanishi Yasuhiko Kita Tsukasa Matsubara Masahiro Iwamoto Toshiharu Shoji Toshiyuki Okada Désirée van der Heijde Nobuyuki Miyasaka Takao Koike

OBJECTIVES To evaluate efficacy and safety of combination therapy using certolizumab pegol (CZP) and methotrexate (MTX) as first-line treatment for MTX-naive, early rheumatoid arthritis (RA) with poor prognostic factors, compared with MTX alone. METHODS MTX-naive, early RA patients with ≤12 months persistent disease, high anti-cyclic citrullinated peptide, and either rheumatoid factor positiv...

2017
Hal A. Lewis Kathleen M. Nemer Rebecca J. Chibnall Amy C. Musiek

H&E: hematoxylin-eosin stain MTX: methotrexate RA: rheumatoid arthritis INTRODUCTION Methotrexate (MTX) is a commonly prescribed medication in the treatment of autoimmune conditions such as rheumatoid arthritis (RA) and psoriasis. MTX is a folic acid analog and DNA synthesis inhibitor that competitively inhibits dihydrofolate reductase. Well-known side effects of MTX include diarrhea, nausea/vo...

2007
J. Braun P. Kästner P. Flaxenberg J. Währisch P. Hanke W. Demary U. von Hinüber K. Rockwitz W. Heitz U. Pichlmeier C. Guimbal-Schmolck

Objective. To compare the efficacy and safety of subcutaneous (SC) versus oral administration of methotrexate (MTX) in patients with active rheumatoid arthritis (RA). Methods. MTX-naive patients with active RA (Disease Activity Score in 28 joints >4) were eligible for the study if they had not previously taken biologic agents and had not taken disease-modifying antirheumatic drugs for 2 weeks p...

Journal: :Cancer research 2004
Pauline Breedveld Noam Zelcer Dick Pluim Ozgür Sönmezer Matthijs M Tibben Jos H Beijnen Alfred H Schinkel Olaf van Tellingen Piet Borst Jan H M Schellens

The antifolate drug methotrexate (MTX) is transported by breast cancer resistance protein (BCRP; ABCG2) and multidrug resistance-associated protein1-4 (MRP1-4; ABCC1-4). In cancer patients, coadministration of benzimidazoles and MTX can result in profound MTX-induced toxicity coinciding with an increase in the serum concentrations of MTX and its main metabolite 7-hydroxymethotrexate. We hypothe...

Journal: :Cancer research 1985
G Fabre I D Goldman

The rapid synthesis of poly-gamma-glutamyl derivatives of 7-hydroxymethotrexate (7-OH-MTX) and their selective intracellular retention are reported in human chronic myelogenous leukemia cells, K-562. After a 30-min exposure to 5 microM [3H]7-OH-MTX, three different polyglutamyl derivatives were detected by high-performance liquid chromatography. When extracellular 7-OH-MTX was removed, the 7-OH...

Journal: :Blood 2013
Susanne Radtke Oliver Zolk Bertold Renner Marios Paulides Martin Zimmermann Anja Möricke Martin Stanulla Martin Schrappe Thorsten Langer

The pharmacogenetics of methotrexate (MTX) was investigated in a large cohort of pediatric patients with acute lymphoblastic leukemia (ALL). Four hundred ninety-nine children with ALL from the ALL-BFM (Berlin-Frankfurt-Münster) 2000 trial who received 1996 courses of MTX at 5 g/m(2) were genotyped for 8 single nucleotide polymorphisms in 5 candidate genes of the MTX/folate pathway. Patients' MT...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید